InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research report sent to investors on Tuesday. The firm issued a sell rating on the stock.

Separately, Lake Street Capital started coverage on InspireMD in a research report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 target price on the stock.

InspireMD Trading Down 1.8 %

NYSE:NSPR opened at $2.75 on Tuesday. The company has a market capitalization of $81.65 million, a P/E ratio of -3.67 and a beta of 0.88. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.80. The business’s 50-day moving average is $2.86 and its 200 day moving average is $2.76.

Institutional Investors Weigh In On InspireMD

Large investors have recently added to or reduced their stakes in the stock. Parkman Healthcare Partners LLC grew its stake in shares of InspireMD by 721.2% during the fourth quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company’s stock valued at $2,248,000 after buying an additional 750,635 shares during the last quarter. Affiance Financial LLC grew its stake in shares of InspireMD by 2.9% during the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock valued at $497,000 after buying an additional 5,376 shares during the last quarter. Essex Investment Management Co. LLC bought a new position in shares of InspireMD during the fourth quarter valued at approximately $191,000. Northern Trust Corp grew its stake in shares of InspireMD by 103.7% during the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after buying an additional 24,452 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its stake in InspireMD by 153.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock worth $79,000 after purchasing an additional 18,233 shares in the last quarter. 44.78% of the stock is owned by institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.